Raymond James reiterates Aardvark Therapeutics stock rating on dosing path By Investing.com

Aardvark paused its Phase 3 HERO trial (and related open-label extension) and Phase 2 obesity trials after cardiac safety signals in a healthy volunteer study; shares trade at $3.58, down 24% over the past week and near a 52-week low of $4.01. Raymond James reiterated a Strong Buy with a $28 price target and expects FDA clarity next quarter, but several firms cut targets sharply (B.Riley $32-> $8, BTIG $26-> $9, BofA $25-> $21) while maintaining Buy/Overweight ratings. Company market cap is roughly $88M, Q4 2025 cash was $110M (stock trading below cash), and free cash flow is negative ~$45M; Raymond James noted a likely need to reduce dose (e.g., to 200mg BID) and potential for additional dose-ranging studies.

Analysis

The market is treating this story as a binary regulatory event: absent mechanistic clarity, probability-weighted NPV collapses because investors apply heavy penalty rates to programs requiring additional dose-ranging or repeat pivotal work. That creates a compressed timeframe where near-term information flow (sponsor/FDA interactions, targeted PK/PD analyses) will dominate price discovery more than underlying science for weeks-to-months.

A credible lower-dose path that preserves on-target efficacy would be disproportionately valuable relative to the current price — upside is convex because successful mitigation lets the company avoid a full re-run of registrational work. Conversely, the larger industry second-order impact is procedural: expect CRO timelines and e-CRF bandwidth to shift as sponsors request deeper cardiac-safety characterization, slowing initiation of other small-molecule programs and lifting demand for specialized cardiotoxicity assays.

Tail risk centers on a regulatory-imposed redo of dose-ranging which would push commercial launch horizons by 12–24 months and materially dilute optionality if follow-on financing is needed; a complete clinical hold is low-probability but high-impact. What would reverse the trade is a clear exposure–response curve tied to a non-off-target mechanism or a targeted formulation change that demonstrably separates efficacy from systemic exposure — that outcome is binary and can rerate the equity by multiple turns quickly.

Key Decisions for Investors

• AARD — Buy asymmetric downside protection: purchase 3–6 month puts sized to 1–2% of portfolio (or a put spread to cap premium). Rationale: short-dated regulatory uncertainty is the dominant driver; limited premium buys time until clarity. Reward: protects against a >40% move lower; cost is limited to premium.
• AARD — Small asymmetric long: deploy a limited-size 6–9 month call spread (debit) as a lottery ticket that pays >3x if management presents a credible lower-dose PK/PD story. Position size 0.5–1% of portfolio. Risk = premium; reward = binary rerating on positive readouts.
• AARD / XBI — Pair trade: short AARD equity (size 1–2% net) and buy equivalent beta in XBI to hedge sector moves. This isolates idiosyncratic regulatory risk while keeping biotech exposure. Exit: unwind on formal FDA guidance or if AARD publishes mechanistic dose–response within 30–90 days.
• Event arbitrage — Monitor for M&A/opportunism: if implied market value approaches liquidation/asset-recovery levels, prepare to accumulate a tactical long stake (<2% portfolio) ahead of potential buyer/partner activity. Catalyst window: next regulatory disclosures over coming months; risk is execution and further dilution.